Tag: azithromycin

1. Hydroxychloroquine use in hospitalized and tocilizumab use in ICU lab-positive COVID-19 patients were not been associated with decreased death. Evidence Rating Level: 2 (Good) There is ongoing research into evaluating potential treatment options for COVID-19. Despite conflicting evidence, hydroxychloroquine (with or without azithromycin) remains a popular option, while  preliminary results...
1. Metformin was found to be safe and tolerable in survivors of pediatric brain tumors. 2. Metformin was associated with retention of memory and processing speed abilities, as well as a reduction of white matter loss. Evidence Rating Level: 1 (Excellent) It is believed that endogenous neural precursor cells (NPCs) can promote...
1. Hydroxychloroquine use with or without azithromycin did not improve clinical outcomes at fifteen days when compared with standard of care in hospitalized patients with mild-to-moderate Covid-19. 2. A higher rate of side effects – including QT prolongation and elevated liver enzymes - was observed in patients taking hydroxychloroquine alone...
1. Use of hydroxychloroquine with or without azithromycin to treat COVID-19 was frequently associated with QTc prolongation, with results being more pronounced for patients taking both hydroxychloroquine and azithromycin. 2. Likelihood of QTc prolongation was greater with concomitant usage of loop diuretics. Evidence Rating: 2 (Good) Although studies have found varying degrees of...
1. Use of hydroxychloroquine with or without azithromycin to treat COVID-19 was frequently associated with QTc prolongation, with results being more pronounced for patients taking both hydroxychloroquine and azithromycin. 2. Likelihood of QTc prolongation was greater with concomitant usage of loop diuretics. Evidence Rating: 2 (Good) Although studies have found varying degrees...
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial 1. Adults with severe COVID-19 treated with remdesivir had numerically faster time to clinical improvement compared to controls, but the difference was not statistically significant Evidence Rating: 1 (Excellent) Months into declaration of COVID-19 as a pandemic, there still remains...
1. Hydroxychloroquine treatment was found to significantly reduce viral load in COVID-19 patients, and had an enhanced effect when azithromycin was included in treatment Evidence Rating: 4 (Below Average) Despite significant research efforts, there currently exists no approved pharmacolgic therapy for the direct treatment of COVID-19 to reduce viral load. Significant...
1. Mass, twice-yearly administration of azithromycin to children between 1 and 59 months of age in communities in Niger previously not administered azithromycin significantly reduced childhood mortality rates. 2. Communities given azithromycin for a third year, after receiving it the previous 2 years, had no significant change in childhood mortality...
1. Mass, twice-yearly administration of azithromycin to children between 1 and 59 months of age in communities in Niger previously not administered azithromycin significantly reduced childhood mortality rates. 2. Communities given azithromycin for a third year, after receiving it the previous 2 years, had no significant change in childhood mortality...
1. Non-inferiority of azithromycin was not established as compared to doxycycline in treating chlamydial infections, likely due to the 100% efficacy of doxycycline, as the efficacy was 97% for azithromycin. 2. However, given the closed population with direct observed treatment and per-protocol primary analysis, it is not clear if...